Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma

Ma,Ruimin; Zhang,Guojun; Wang,Huimin; Lv,Hong; Fang,Fang; Kang,Xixiong

doi:10.3892/ol.2012.918

Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma

Authors:
- Ruimin Ma
- Guojun Zhang
- Huimin Wang
- Hong Lv
- Fang Fang
- Xixiong Kang
View Affiliations

Affiliations: Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Dongcheng, Beijing 100050, P.R. China, Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Dongcheng, Beijing 100050, P.R. China, Department of Cadres Health Care, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010017, P.R. China
Published online on: September 14, 2012 https://doi.org/10.3892/ol.2012.918
Pages: 1321-1324

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Low-grade glioma is predisposed to progress to anaplastic astrocytoma and eventually secondary glioblastoma. The malignant transformation may involve the accumulation of multiple genetic alterations. The purpose of this study was to explore the role of miR-544 in glioma progression and discuss whether it may be a novel biomarker of malignant transformation. The expression of miR-544 was measured in a series of 198 glioma samples (63 low-grade glioma, 44 anaplastic astrocytoma and 91 glioblastoma tumors) using microarrays. Quantitative real-time reverse transcription PCR (qRT-PCR) was used to validate the expression levels of miR-544 in tissue and serum samples in an independent validated cohort (25 low-grade glioma, 21 anaplastic astrocytoma and 20 glioblastoma tumors). A Pearson correlation analysis was performed to examine the correlation between miR-544 levels of tissue and serum samples. Microarrays revealed that the expression levels of miR-544 decreased significantly in anaplastic gliomas (P<0.01) or glioblastoma (P<0.01) compared with low-grade gliomas. In an independent cohort of glioma patients, miR-544 exhibited a progression‑associated downregulation in glioma tumors. The levels of miR-544 in serum samples tended to be lower in anaplastic and glioblastoma patients compared with low-grade gliomas, but with no significant difference. The Pearson correlation analysis revealed a weakly positive correlation between tissue and serum levels of miR-544. These data support a significant role for miR-544 aberration in the malignant transformation of glioma. The downregulation of miR-544 in tissue may be used as a novel biomarker.

View Figures

View References

1.	O MartinhoS GranjaT JaraquemadaDownregulation of RKIP is associated with poor outcome and malignant progression in gliomasPLoS One7e30769201210.1371/journal.pone.003076922292035
2.	DN LouisH OhgakiOD WiestlerThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol11497109200710.1007/s00401-007-0243-417618441
3.	B MalzkornM WolterF LiesenbergIdentification and functional characterization of microRNAs involved in the malignant progression of gliomasBrain Pathol20539550201010.1111/j.1750-3639.2009.00328.x19775293
4.	L CastellanoG GiamasJ JacobThe estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional responseProc Natl Acad Sci USA1061573215737200910.1073/pnas.0906947106
5.	W FilipowiczSN BhattacharyyaN SonenbergMechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?Nat Rev Genet9102114200810.1038/nrg229018197166
6.	Y ZhangA DuttaR AbounaderThe role of microRNAs in glioma initiation and progressionFront Biosci17700712201210.2741/395222201769
7.	JS McDonaldD MilosevicHV ReddiSK GrebeA Algeciras-SchimnichAnalysis of circulating microRNA: preanalytical and analytical challengesClin Chem57833840201110.1373/clinchem.2010.15719821487102
8.	Z HuX ChenY ZhaoSerum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancerJ Clin Oncol2817211726201010.1200/JCO.2009.24.934220194856
9.	K WatanabeK SatoW BiernatIncidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsiesClin Cancer Res352353019979815715
10.	TY JungS JungJH MoonIY KimKS MoonWY JangEarly prognostic factors related to progression and malignant transformation of low-grade gliomasClin Neurol Neurosurg113752757201110.1016/j.clineuro.2011.08.00221889256
11.	R StuppM ReniG GattaE MazzaC VechtAnaplastic astrocytoma in adultsCrit Rev Oncol Hematol637280200710.1016/j.critrevonc.2007.03.003
12.	M WellerU MalipieroA AguzziJC ReedA FontanaProtooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiationJ Clin Invest9526332643199510.1172/JCI117965
13.	H OhgakiP KleihuesGenetic pathways to primary and secondary glioblastomaAm J Pathol17014451453200710.2353/ajpath.2007.07001117456751
14.	FB FurnariT FentonRM BachooMalignant astrocytic glioma: genetics, biology, and paths to treatmentGenes Dev2126832710200710.1101/gad.159670717974913
15.	RG WeberM SabelJ ReifenbergerCharacterization of genomic alterations associated with glioma progression by comparative genomic hybridizationOncogene1398399419968806688
16.	SH BignerMR MatthewsBK RasheedMolecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridizationAm J Pathol155375386199910.1016/S0002-9440(10)65134-6
17.	DW ParsonsS JonesX ZhangAn integrated genomic analysis of human glioblastoma multiformeScience32118071812200810.1126/science.116438218772396
18.	A ContiM AguennouzD La TorremiR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumorsJ Neurooncol93325332200919159078
19.	L ShiZ ChengJ Zhanghsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cellsBrain Res1236185193200810.1016/j.brainres.2008.07.08518710654
20.	C QuintavalleM GarofaloC ZancamiR-221/222 over-expession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmuOncogene31858868201210.1038/onc.2011.28021743492
21.	ST LeeK ChuHJ OhLet-7 microRNA inhibits the proliferation of human glioblastoma cellsJ Neurooncol1021924201110.1007/s11060-010-0286-620607356
22.	SA RaoV SantoshK SomasundaramGenome-wide expression profiling identifies deregulated miRNAs in malignant astrocytomaMod Pathol2314041417201010.1038/modpathol.2010.13520711171
23.	V ThayanithyAL SarverRV KarthaPerturbation of 14q32 miRNAs-cMYC gene network in osteosarcomaBone50171181201210.1016/j.bone.2011.10.01222037351
24.	JC BraseM JohannesT SchlommCirculating miRNAs are correlated with tumor progression in prostate cancerInt J Cancer128608616201110.1002/ijc.2537620473869
25.	EK NgWW ChongH JinDifferential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screeningGut5813751381200910.1136/gut.2008.16781719201770
26.	CC YangPS HungPW WangmiR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinomaJ Oral Pathol Med40397404201110.1111/j.1600-0714.2010.01003.x21244495
27.	LM WulfkenR MoritzC OhlmannMicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levelsPLoS One6e25787201110.1371/journal.pone.002578721984948
28.	L PigatiSC YaddanapudiR IyengarSelective release of microRNA species from normal and malignant mammary epithelial cellsPLoS One5e13515201010.1371/journal.pone.001351520976003
29.	K ZenCY ZhangCirculating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancersMed Res Rev32326348201210.1002/med.2021522383180